Regulatory milestones

Cornerstone Therapeutics Inc. (NASDAQ:CRTX) fell $1.37 (21%) to $5.10 on Thursday after FDA's Cardiovascular and Renal Drugs Advisory Committee recommended against approval of lixivaptan to treat hypervolemic hyponatremia associated with chronic heart failure (CHF) and euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH). The committee voted 8-0 against the CHF indication and 5-3 against the SIADH indication. The product has an Oct. 29 PDUFA date.